Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Fibrogenesis & Tissue Repair
Published in: Fibrogenesis & Tissue Repair 1/2012

Open Access 01-12-2012 | Proceedings

Reversal of transforming growth factor-β induced epithelial-to-mesenchymal transition and the ZEB proteins

Authors: Shreyasi Das, Bryan N Becker, F Michael Hoffmann, Janet E Mertz

Published in: Fibrogenesis & Tissue Repair | Special Issue 1/2012

Login to get access

Abstract

Background

The dynamic process of epithelial-to-mesenchymal transition (EMT) is a causal event in kidney fibrosis. This cellular phenotypic transition involves activation of transcriptional responses and remodeling of cellular structures to change cellular function. The molecular mechanisms that directly contribute to the re-establishment of the epithelial phenotype are poorly understood.

Results

Here, we discuss recent studies from our group and other laboratories identifying signaling pathways leading to the reversal of EMT in fibrotic models. We also present evidence that transcriptional factors such as the ZEB proteins are important regulators for reversal of EMT.

Conclusion

These studies provide insights into cellular plasticity and possible targets for therapeutic intervention.
Literature
1.
Brenner BM, Rector F: Brenner and Rector's The Kidney. 2008, Philidelphia: Saunders, 8
2.
Zeisberg M, Kalluri R: Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol. 2008, 23 (9): 1395-1398. 10.1007/s00467-008-0818-x.CrossRefPubMed
3.
4.
Bedi S, Vidyasagar A, Djamali A: Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosis. Transplant Rev (Orlando). 2008, 22 (1): 1-5.PubMedCentralCrossRefPubMed
5.
Savagner P: Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 2001, 23 (10): 912-923. 10.1002/bies.1132.CrossRefPubMed
6.
Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003, 15 (6): 740-746. 10.1016/j.ceb.2003.10.006.CrossRefPubMed
7.
Moustakas A, Heldin CH: Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007, 98 (10): 1512-1520. 10.1111/j.1349-7006.2007.00550.x.CrossRefPubMed
8.
Zeisberg M, Maeshima Y, Mosterman B, Kalluri R: Renal fibrosis. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol. 2002, 160 (6): 2001-2008. 10.1016/S0002-9440(10)61150-9.PubMedCentralCrossRefPubMed
9.
Yang J, Liu Y: Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol. 2001, 159 (4): 1465-1475. 10.1016/S0002-9440(10)62533-3.PubMedCentralCrossRefPubMed
10.
Turley EA, Veiseh M, Radisky DC, Bissell MJ: Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?. Nat Clin Pract Oncol. 2008, 5 (5): 280-290.PubMedCentralCrossRefPubMed
11.
Gal A, Sjoblom T, Fedorova L, Imreh S, Beug H, Moustakas A: Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene. 2008, 27 (9): 1218-1230. 10.1038/sj.onc.1210741.CrossRefPubMed
12.
Tse JC, Kalluri R: Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem. 2007, 101 (4): 816-829. 10.1002/jcb.21215.CrossRefPubMed
13.
Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL: Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science. 2005, 307 (5715): 1603-1609. 10.1126/science.1105718.CrossRefPubMed
14.
15.
Massague J, Gomis RR: The logic of TGFbeta signaling. FEBS Lett. 2006, 580 (12): 2811-2820. 10.1016/j.febslet.2006.04.033.CrossRefPubMed
16.
Jayaraman L, Massague J: Distinct oligomeric states of SMAD proteins in the transforming growth factor-beta pathway. J Biol Chem. 2000, 275 (52): 40710-40717. 10.1074/jbc.M005799200.CrossRefPubMed
17.
Chacko BM, Qin BY, Tiwari A, Shi G, Lam S, Hayward LJ, De Caestecker M, Lin K: Structural basis of heteromeric smad protein assembly in TGF-beta signaling. Mol Cell. 2004, 15 (5): 813-823. 10.1016/j.molcel.2004.07.016.CrossRefPubMed
18.
Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS: SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002, 62 (1): 65-74. 10.1124/mol.62.1.65.CrossRefPubMed
19.
Halder SK, Beauchamp RD, Datta PK: A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia. 2005, 7 (5): 509-521. 10.1593/neo.04640.PubMedCentralCrossRefPubMed
20.
Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P: TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci. 1999, 112 (Pt 24): 4557-4568.PubMed
21.
Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, Morishita R, Johnson RJ: Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol. 2003, 14 (6): 1535-1548. 10.1097/01.ASN.0000067632.04658.B8.CrossRefPubMed
22.
Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP: Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. Embo J. 2004, 23 (5): 1155-1165. 10.1038/sj.emboj.7600069.PubMedCentralCrossRefPubMed
23.
24.
Zeisberg M, Kalluri R: The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med. 2004, 82 (3): 175-181. 10.1007/s00109-003-0517-9.CrossRefPubMed
25.
Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003, 425 (6958): 577-584. 10.1038/nature02006.CrossRefPubMed
26.
Massague J, Seoane J, Wotton D: Smad transcription factors. Genes Dev. 2005, 19 (23): 2783-2810. 10.1101/gad.1350705.CrossRefPubMed
27.
Boden SD, Zdeblick TA, Sandhu HS, Heim SE: The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine (Phila Pa 1976). 2000, 25 (3): 376-381. 10.1097/00007632-200002010-00020.CrossRef
28.
Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R: BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 2003, 9 (7): 964-968. 10.1038/nm888.CrossRefPubMed
29.
Itoh S, Thorikay M, Kowanetz M, Moustakas A, Itoh F, Heldin CH, ten Dijke P: Elucidation of Smad requirement in transforming growth factor-beta type I receptor-induced responses. J Biol Chem. 2003, 278 (6): 3751-3761. 10.1074/jbc.M208258200.CrossRefPubMed
30.
Yang J, Dai C, Liu Y: A Novel Mechanism by which Hepatocyte Growth Factor Blocks Tubular Epithelial to Mesenchymal Transition. J Am Soc Nephrol. 2005, 16 (1): 68-78.CrossRefPubMed
31.
Yang J, Dai C, Liu Y: Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol. 2003, 163 (2): 621-632. 10.1016/S0002-9440(10)63689-9.PubMedCentralCrossRefPubMed
32.
Mizuno S, Nakamura T: Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy. Am J Physiol Renal Physiol. 2004, 286 (1): F134-143.CrossRefPubMed
33.
Yang J, Liu Y: Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol. 2003, 284 (2): F349-357.CrossRefPubMed
34.
Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grunert S: Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol. 2002, 156 (2): 299-313. 10.1083/jcb.200109037.PubMedCentralCrossRefPubMed
35.
Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL: Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia. 2004, 6 (5): 603-610. 10.1593/neo.04241.PubMedCentralCrossRefPubMed
36.
Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL: p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J Cell Sci. 2002, 115 (Pt 15): 3193-3206.PubMed
37.
Brown K, Bhowmick NA: Linking TGF-beta-mediated Cdc25A inhibition and cytoskeletal regulation through RhoA/p160(ROCK) signaling. Cell Cycle. 2004, 3 (4): 408-410.CrossRefPubMed
38.
Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A: TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell. 2005, 16 (4): 1987-2002. 10.1091/mbc.E04-08-0658.PubMedCentralCrossRefPubMed
39.
Grande M, Franzen A, Karlsson JO, Ericson LE, Heldin NE, Nilsson M: Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes. J Cell Sci. 2002, 115 (Pt 22): 4227-4236.CrossRefPubMed
40.
Das S, Becker BN, Hoffmann FM, Mertz JE: Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway. BMC Cell Biol. 2009, 10: 94-10.1186/1471-2121-10-94.PubMedCentralCrossRefPubMed
41.
Eger A, Stockinger A, Park J, Langkopf E, Mikula M, Gotzmann J, Mikulits W, Beug H, Foisner R: beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene. 2004, 23 (15): 2672-2680.CrossRefPubMed
42.
Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000, 2 (2): 84-89. 10.1038/35000034.CrossRefPubMed
43.
Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla SM, Villa S, Bolos V, Jorda M, Fabra A, Portillo F, et al: Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res. 2006, 66 (19): 9543-9556. 10.1158/0008-5472.CAN-06-0479.CrossRefPubMed
44.
Shirakihara T, Saitoh M, Miyazono K: Differential regulation of epithelial and mesenchymal markers by deltaEF1 proteins in epithelial mesenchymal transition induced by TGF-beta. Mol Biol Cell. 2007, 18 (9): 3533-3544. 10.1091/mbc.E07-03-0249.PubMedCentralCrossRefPubMed
45.
Aigner K, Descovich L, Mikula M, Sultan A, Dampier B, Bonne S, van Roy F, Mikulits W, Schreiber M, Brabletz T, et al: The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett. 2007, 581 (8): 1617-1624. 10.1016/j.febslet.2007.03.026.PubMedCentralCrossRefPubMed
46.
Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, Berx G, Cano A, Beug H, Foisner R: DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene. 2005, 24 (14): 2375-2385. 10.1038/sj.onc.1208429.CrossRefPubMed
47.
Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer. 2007, 7 (6): 415-428. 10.1038/nrc2131.CrossRefPubMed
48.
Vandewalle C, Van Roy F, Berx G: The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci. 2009, 66 (5): 773-787. 10.1007/s00018-008-8465-8.CrossRefPubMed
49.
Van de Putte T, Maruhashi M, Francis A, Nelles L, Kondoh H, Huylebroeck D, Higashi Y: Mice lacking ZFHX1B, the gene that codes for Smad-interacting protein-1, reveal a role for multiple neural crest cell defects in the etiology of Hirschsprung disease-mental retardation syndrome. Am J Hum Genet. 2003, 72 (2): 465-470. 10.1086/346092.PubMedCentralCrossRefPubMed
50.
Ahn SM, Cha JY, Kim J, Kim D, Trang HT, Kim YM, Cho YH, Park D, Hong S: Smad3 regulates E-cadherin via miRNA-200 pathway. Oncogene. 2011
51.
Xiong M, Jiang L, Zhou Y, Qiu W, Fang L, Tan R, Wen P, Yang J: MiR-200 family regulates TGF-{beta}1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol. 2011
52.
Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, Sarkar FH: Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One. 2010, 5 (8): e12445-10.1371/journal.pone.0012445.PubMedCentralCrossRefPubMed
53.
Liu Y, El-Naggar S, Darling DS, Higashi Y, Dean DC: Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development. 2008, 135 (3): 579-588. 10.1242/dev.007047.PubMedCentralCrossRefPubMed
54.
Postigo AA, Dean DC: Differential expression and function of members of the zfh-1 family of zinc finger/homeodomain repressors. Proc Natl Acad Sci USA. 2000, 97 (12): 6391-6396. 10.1073/pnas.97.12.6391.PubMedCentralCrossRefPubMed
55.
Korpal M, Lee ES, Hu G, Kang Y: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008, 283 (22): 14910-14914. 10.1074/jbc.C800074200.PubMedCentralCrossRefPubMed
Metadata
Title
Reversal of transforming growth factor-β induced epithelial-to-mesenchymal transition and the ZEB proteins
Authors
Shreyasi Das
Bryan N Becker
F Michael Hoffmann
Janet E Mertz
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Fibrogenesis & Tissue Repair / Issue Special Issue 1/2012
Electronic ISSN: 1755-1536
DOI
https://doi.org/10.1186/1755-1536-5-S1-S28

Other articles of this Special Issue 1/2012

Fibrogenesis & Tissue Repair 1/2012 Go to the issue

Proceedings

Progression of renal fibrosis: the underestimated role of endothelial alterations

Proceedings

Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo

Proceedings

Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis

Proceedings

Fibrocytes and the pathogenesis of diffuse parenchymal lung disease

Proceedings

The myofibroblast, multiple origins for major roles in normal and pathological tissue repair

Proceedings

Hypoxia-inducible factor signaling in the development of kidney fibrosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits